Krystal Biotech: Vyjuvek Gene Therapy Well Positioned For Growth [Seeking Alpha]
Krystal Biotech, Inc. (KRYS)
Last krystal biotech, inc. earnings: 11/4 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.krystalbio.com/investors
Company Research
Source: Seeking Alpha
Vyjuvek's US sales growth has plateaued, but international rollouts in Europe and Japan are expected to drive further sales growth, with management targeting $1B in peak sales. KRYS pipeline catalysts include KB803 (ophthalmology), KB407 (cystic fibrosis), and KB801 (neurotrophic keratitis), with key data readouts over the next year. While past growth has been exceptional, further upside depends on successful global Vyjuvek expansion and pipeline execution. Meeting expectations implies a 12-month price target of $219.50/share. j9prin/iStock via Getty Images Last December , I initiated coverage on Krystal Biotech ( KRYS ) as a STRONG BUY following a robust commercial launch for the company's gene therapy Vyjuvek. Since the stock has appreciated from $161/share to around $207/share (a 29% gain This article was written by Analyst's Disclosure: I/we have a beneficial long position in the shares of KRYS either through stock ownership, options, or other derivatives. I wrote thi
Show less
Read more
Impact Snapshot
Event Time:
KRYS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KRYS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KRYS alerts
High impacting Krystal Biotech, Inc. news events
Weekly update
A roundup of the hottest topics
KRYS
News
- Krystal Biotech (NASDAQ:KRYS) had its "hold (c+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Krystal Biotech to Present at 8th Annual Evercore Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Krystal Biotech to Present at 8th Annual Evercore Healthcare ConferenceGlobeNewswire
- Evercore ISI Reiterates Buy Rating on Krystal Biotech (KRYS), Sets $218 PT [Yahoo! Finance]Yahoo! Finance
- Krystal Biotech (NASDAQ:KRYS) had its "hold (c+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
KRYS
Earnings
- 11/3/25 - Beat
KRYS
Sec Filings
- 12/5/25 - Form 4
- 12/5/25 - Form 4
- 12/4/25 - Form 144
- KRYS's page on the SEC website